表紙
市場調査レポート

ナノ医薬品の産業および市場:企業・製品・R&D・収益の予測 (2015-2025年)

Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025

発行 Visiongain Ltd 商品コード 339747
出版日 ページ情報 英文 131 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.53円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
ナノ医薬品の産業および市場:企業・製品・R&D・収益の予測 (2015-2025年) Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025
出版日: 2015年09月17日 ページ情報: 英文 131 Pages
概要

2015年以降、ナノ技術を用いた製品には投資・需要・売上の大きな機会があると考えられています。世界のナノ医薬品の市場は2017年には1300億ドルの規模に達すると予測されており、また、2015年から2025年にかけての大幅な収益の拡大も見込まれています。

当レポートでは、世界のナノ医薬品の市場について調査し、ナノ医薬品の定義と概要、重要性、各種用途、治療区分・主な上市済み製品・主要国別の収益予測、主要関連企業のプロファイル、パイプラインの動向、定性分析、専門家へのインタビューなどをまとめています。

第1章 レポート概要

第2章 イントロダクション:ナノ医薬品

  • ナノ技術:定義
  • ナノ医薬品
  • ナノ技術:医薬品におけるソリューションと改良点
  • ナノ医薬品の各種用途
    • 薬剤送達
    • ナノ薬剤
      • ナノ粒子:3つの側面の組み合わせ
        • リポソーム
        • ポリマー
        • 量子ドット
        • SPIO (Superparamagnetic Iron Oxide)
        • カーボンナノチューブ
        • カーボンナノシェル
      • ナノ粒子の機能付与
        • 標的化
        • 表面結合
        • バイオアベイラビリティの改善
        • 可同調性
        • 放出制御
    • インプラント
    • 診断
      • 診断ツール
      • イメージングツール
      • セラノスティクス

第3章 世界市場の予測

  • 収益予測:治療区分別
    • 心臓血管系
    • 抗炎症用途
    • 神経系
    • 抗感染用途
    • その他

第4章 主な製品の商業的展望

  • 製品区分
    • 上市済み製品の収益予測
      • Abraxane (Celgene)
      • Doxil (Janssen)
      • Myocet (Teva Pharmaceuticals)
      • ONCASPAR (Baxalta)
      • Alimta (Eli Lilly)
      • Eligard (Sanofi)
      • DaunoXome (Galen)
      • Copaxone (Teva)
      • Rapamune (PF Prism)
      • Neulasta (Amgen)
      • Cimzia (UCB)
      • AmBisome (アステラス製薬)
      • MIRCERA (Roche)
      • Pegasys (Roche)
      • Emend (Merck)
      • Renagel (Genzyme)
      • Ritalin (Novartis)

第5章 主要国市場の予測

  • ナノ医薬品:主要市場の実績
  • 米国市場の予測
  • 日本市場の予測
  • EU市場の予測
  • アジア太平洋市場の予測
  • その他の地域市場の予測

第6章 ナノ技術を用いる医薬品企業のプロファイル

  • Sanofi
  • BIND Therapeutics
  • Merck
  • Pfizer
  • Cerulean Pharma
  • Selecta Biosciences
  • Nanobiotix
  • Magforce
  • Celgene
  • Celsion Corporation
  • Nanocarrier

第7章 R&D

  • ナノ粒子・ナノ技術によって実現する薬剤のパイプライン
    • DermaVir (Genetic Immunity)
    • CRLX101(Cerulean Pharma)
    • CPX-351(Celator Pharma)
    • NC-6004(NanoCarrier Co.)
    • NK-105(日本化薬)
    • NK-012(日本化薬)
    • SGT-53(SynerGene Therapeutics)
    • BIND-014(BIND Biosciences)
    • ThermoDox (Celsion)
    • ADI-PEG 20(Polaris)

第8章 ナノ医薬品市場の定性分析

  • 改善の余地
    • 安全性と毒性
    • 体制と提携関係の確立
    • 法規制:明確なガイドラインとハーモナイゼーションの必要性

第9章 専門家へのインタビュー

第10章 総論

図表

目次
Product Code: PHA0065

Nanopharma - Discover Revenue Prospects Now, Benefiting Your Authority

Do you want to find sales potentials of nanomedicine? If so, our new analysis gives you revenue forecasts to 2025 at overall world market, application, product and national level. That way you discover financial data, trends, R&D, opportunities and commercial outlooks.

Visiongain's study gives you revenue predictions from 2015 for nano-enabled drugs. There you explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight. Discover what the future holds, staying ahead.

Our work explains the potential of nanomedicine to change pharma. See how those developments affect patients, healthcare providers and pharmaceutical companies.

Please read on to explore what drives and shapes that industry, also seeing revenue prediction.


Forecasts and other analysis show you where the best sales opportunities exist

Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You explore quantitative and qualitative analyses, business news, research and development. You gain 34 tables, 44 charts and three interviews with other experts.

With that study you assess clinical, technological and commercial trends, results and potentials:

  • Why will the nanopharma market expand fast - and what future revenues are possible?
  • When will that worldwide industry achieve overall sales in hundreds of billion dollars?
  • What products give the most promise for developers, producers and sellers?
  • Who are the best-placed companies in that healthcare industry from 2015?
  • Where are the most lucrative regions for selling those medicines?
  • How will nanotechnological advances affect drug developers, marketers and manufacturers?

Many opportunities exist in healthcare for applications of nanotechnology. With our study you discover what segments are most likely to prosper. See potential sales from 2015.

Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With our research and analysis, see how to save time and benefit your authority on nanomedicine.

That way you explore what the future holds for nanopharma. The following sections outline how our new investigation helps your work.

Predictions for that world market and submarkets - what sales growth is possible?

Along with revenue prediction for the overall world market for nanopharmaceuticals, our investigation shows you forecasts to 2025 for six individual therapeutic submarkets:

  • Cancer
  • Cardiovascular disorders
  • Central nervous system (CNS) conditions
  • Infectious diseases
  • Inflammation
  • Other applications of nanotechnology in pharmacotherapy.

Our report analyses sales potentials of those technological advances, showing how companies gain. That work can also benefit your authority on nanomedical applications, expanding your reputation for commercial and technological knowledge.

The new investigation discusses what stimulates and restrains sales of those treatments. You explore that industry, also seeing what products can achieve the most success.

Forecasting of leading products' sales - what revenues are possible for nanodrugs?

How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of 13 brands:

  • Abraxane
  • Alimta
  • Eligard
  • Copaxone
  • Rapamune
  • Neulasta
  • Cimzia.

Our sales predictions also cover these products:

  • AmBisome
  • MIRCERA
  • Pegasys
  • Emend
  • Renagel
  • Ritalin.

That work shows how high sales can go, revealing drugs and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, R&D, competitors and opportunities.

Discover what the future holds. Our study also divides its overall world forecast into geographical segments.

Regional markets for nanomedicine - where will highest sales and growth occur?

Developments worldwide will influence the nano-enabled drugs market, raising demand for those therapies in developed and developing countries. Discover what success is possible.

Our analyses show you individual revenue forecasts to 2025 for five regional markets:

  • United States
  • Japan
  • European Union
  • Asia Pacific
  • Rest of world.

There you discover progress and outlooks. You assess the nanomedical industry's future - needs, developments, demands and their meaning. Our work explains, exploring issues affecting nanotechnological companies, influencing their work, results and potentials.

Forces affecting the nanopharma business - what shapes its present and future?

Our new report discusses pressures, opportunities and other events affecting the nanopharmaceutical industry and market from 2015, including these influences:

  • Prominent nanomedicine companies by region - leading players
  • Systems used in nanotechnology-enabled drug delivery
  • Applications in therapeutics, implants, diagnostics and theranostics
  • Nanoparticles - liposomes, polymers, quantum dots, superparamagnetic iron oxide (SPIO), carbon nanotubes and nanoshells
  • Nanoparticle function, targeting, surface conjugation, improved bioavailability, tunability and controlled release systems
  • Investments, infrastructure, networks and collaborations, as well as outlooks for regulatory guidelines and harmonisation.

Our survey also discusses research and development in nanomedicine, in particular for these product candidates:

  • DermaVir (Genetic Immunity)
  • CRLX101 (Cerulean Pharma)
  • CPX-351 (Celator Pharma)
  • NC-6004 (NanoCarrier)
  • NK-105 (Nippon Kayaku)
  • NK-012 (Nippon Kayaku)
  • SGT-53 (SynerGene Therapeutics)
  • BIND-014 (BIND Biosciences)
  • ThermoDox (Celsion)
  • ADI-PEG 20 (Polaris).

You assess the nanomedicine industry's strengths, weaknesses, opportunities and threats. That way you explore what restricts and stimulates companies, seeing what is possible.

Avoid falling behind. With our investigation you discover what the future holds for nano-enabled drugs, seeing prospects for their designers, producers and sellers.

Leading companies and overall 2017 revenue prediction

From 2015, product launches using nanotechnology hold great potential for investments, demand and sales. Our study predicts the world market for nanopharmaceuticals will reach $130bn in 2017, with strong revenue expansion from 2015 to 2025. Explore the potentials.

Our work assesses nanopharma technologies, products and companies holding the best prospects. You see what is possible for technological advances and revenue expansion.

Those analyses cover these companies and other developers, producers, marketers and technology suppliers:

  • Sanofi
  • BIND Therapeutics
  • Merck
  • Pfizer
  • Cerulean Pharma
  • Selecta Biosciences.

And you assess these nanopharma specialists, among others:

  • Nanobiotix
  • Magforce
  • Celgene
  • Celsion Corporation
  • Nanocarrier.

You also examine three interviews with authorities in these organisations:

  • Swiss Federal Laboratories for Materials Science and Technology
  • Rexahn Pharmaceuticals
  • Cristal Therapeutics.

From 2015 there will arise many opportunities. Our work shows you commercial possibilities for those novel drug technologies, helping you stay ahead in knowledge and succeed.

Ways Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 helps

In the following main ways, our investigation helps your research, analyses, decisions, proposals and presentations:

  • Revenues for nanopharma to 2025 at overall world level and for 6 submarkets and 13 products - find outlooks for R&D, production and sales
  • Forecasts to 2025 for 5 regional markets - assess leading countries and regions for potential revenues, seeing what progress is possible
  • Prospects for established competitors and rising companies - explore portfolios, results, strategies, technologies and outlooks for success
  • Analysis of what encourages and restrains the nanomedicine industry - investigate challenges, strengths and competition affecting revenues and profits
  • Interviews with authorities - discover what other experts think, say and do, helping you stay ahead in technological, medical and commercial insight.

That study - by visiongain's in-house analysts in the UK - gives knowledge to help your work, to spare you hassle and save time. You gain data leading companies depend on.

Information found nowhere else, benefiting your authority on pharma nanotechnology

Our survey gives independent analysis. There you gain competitive intelligence found only in our report, seeing where commercial prospects are most rewarding.

With our data you are less likely to fall behind in information or miss opportunity. Discover there how to benefit your searches, analyses, plans and decisions, also saving time and helping your influence.

So explore the future of nanomedicine. In our investigation you find data, trends, opportunities and multilevel sales predictions. Stay ahead by requesting our new report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Nanomedicine Industry and Market
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by this Analysis
  • 1.5. Who Is This Study For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to Nanomedicine

  • 2.1. Nanotechnology - Definition
  • 2.2. Nanomedicine - Size Should Not be the Main Definition
  • 2.3. Nanotechnology - Solutions and Improvements in Medicine
  • 2.4. Nanomedicine - Types of Applications
    • 2.4.1. Drug Delivery
    • 2.4.2. Nanodrugs
      • 2.4.2.1. Nanoparticles - Combinations of Three Dimensions
        • 2.4.2.1.1. Liposomes
        • 2.4.2.1.2. Polymers
        • 2.4.2.1.3. Quantum Dots
        • 2.4.2.1.4. Superparamagnetic Iron Oxide (SPIO)
        • 2.4.2.1.5. Carbon Nanotubes
        • 2.4.2.1.6. Carbon Nanoshells
      • 2.4.2.2. Nanoparticle Functionalisation
        • 2.4.2.2.1. Targeting
        • 2.4.2.2.2. Surface Conjugation
        • 2.4.2.2.3. Improved Bioavailability
        • 2.4.2.2.4. Tunability
        • 2.4.2.2.5. Controlled Release
    • 2.4.3. Implants
    • 2.4.4. Diagnostics
      • 2.4.4.1. Diagnostic Tools
      • 2.4.4.2. Medical Instruments
      • 2.4.4.3. Imaging Tools
      • 2.4.4.4. Theranostics

3. Global Nanomedicine Market, 2015-2025

  • 3.1. Revenue Forecasts of Nanomedicine by Therapeutic Area
    • 3.1.1. Forecast of Nanomedicine for Oncology 2015-2025
    • 3.1.2. Forecast of Nanomedicine for Cardiovascular Uses 2015-2025
    • 3.1.3. Forecast of Nanomedicine for Anti-inflammatory Uses 2015-2025
    • 3.1.4. Forecast of Nanomedicine for Neurology 2015-2025
    • 3.1.5. Forecast of Nanomedicine for Anti-Infective 2015-2025
    • 3.1.6. Forecast of Nanomedicine for Other Therapeutic Areas 2015-2025

4. Nanomedicine Products - Commercial Outlooks from 2015

  • 4.1. Nanomedicine Products - Segmentation
    • 4.1.1. Nanomedicine Products in the Market - Revenue Potentials, 2015-2025
      • 4.1.1.1. Abraxane (Celgene)
      • 4.1.1.2. Doxil (Janssen)
      • 4.1.1.3. Myocet (Teva Pharmaceuticals)
      • 4.1.1.4. ONCASPAR (Baxalta)
      • 4.1.1.5. Alimta (Eli Lilly)
      • 4.1.1.6. Eligard (Sanofi)
      • 4.1.1.7. DaunoXome (Galen)
      • 4.1.1.8. Copaxone (Teva)
      • 4.1.1.9. Rapamune (PF Prism)
      • 4.1.1.10. Neulasta (Amgen)
      • 4.1.1.11. Cimzia (UCB)
      • 4.1.1.12. AmBisome (Astellas Pharma)
      • 4.1.1.13. MIRCERA (Roche)
      • 4.1.1.14. Pegasys (Roche)
      • 4.1.1.15. Emend (Merck)
      • 4.1.1.16. Renagel (Genzyme)
      • 4.1.1.17. Ritalin (Novartis)

5. Leading National Markets, 2015-2025

  • 5.1. Nanomedicine - Leading Markets, 2014
  • 5.2. The US Nanomedicine Market, 2015-2025
  • 5.3. The Japanese Nanomedicine Market, 2015-2025
  • 5.4. The EU Nanomedicine Market, 2015-2025
  • 5.5. The Asia-Pacific Nanomedicine Market, 2015-2025
  • 5.6. Rest of the World Nanomedicine Market, 2015-2025

6. Profiles of Pharmaceutical Companies with Nanotechnology Related Applications

  • 6.1. Sanofi
  • 6.2. BIND Therapeutics
  • 6.3. Merck
  • 6.4. Pfizer
  • 6.5. Cerulean Pharma
  • 6.6. Selecta Biosciences
  • 6.7. Nanobiotix
  • 6.8. Magforce
  • 6.9. Celgene
  • 6.10. Celsion Corporation
  • 6.11. Nanocarrier

7. Research & Development

  • 7.1. Nanoparticles and Nano-enabled Drugs in the Pipeline
    • 7.1.1. DermaVir (Genetic Immunity)
    • 7.1.2. CRLX101(Cerulean Pharma)
    • 7.1.3. CPX-351(Celator Pharma)
    • 7.1.4. NC-6004(NanoCarrier Co.)
    • 7.1.5. NK-105(Nippon Kayaku Co. Ltd.)
    • 7.1.6. NK-012(Nippon Kayaku Co. Ltd.)
    • 7.1.7. SGT-53(SynerGene Therapeutics)
    • 7.1.8. BIND-014(BIND Biosciences)
    • 7.1.9. ThermoDox (Celsion)
    • 7.1.10. ADI-PEG 20(Polaris)

8. Qualitative Analysis of the Nanomedicine Market, 2015

  • 8.1. Room for Improvement
    • 8.1.1. Safety and Toxicology Often Yet to be Determined
    • 8.1.2. Establishment of Structures and Collaborations
    • 8.1.3. Regulatory - The Need for Clear Guidelines and Harmonization

9. Research Interviews, 2015

  • 9.1. Dr Peter Wick, Empa, the Swiss Federal Laboratories for Materials Science and Technology
    • 9.1.1. Connecting the Key Players in the Nanomedical Sector in Europe
    • 9.1.2. Nanomedicine Industry in Europe - In Need of an Infrastructure
    • 9.1.3. EU-NCL: Bridging the Major Gaps and Challenges
  • 9.2. Dr Peter D. Suzdak, CEO, Rexahn Pharmaceuticals
    • 9.2.1. Precision-Targeted Therapy - Revolutionizes Cancer Treatment
    • 9.2.2. RX-21101 - Included in NCL's Preclinical Characterization Program
    • 9.2.3. Rexahn's NPDCS Technology - Next Generation Approach to Chemotherapy
    • 9.2.4. Rexahn's Polymer-Drug Conjugate - Improves Efficacy and Reduces Side Effects
  • 9.3. Dr Joost Holthuis, CEO, Cristal Therapeutics, Netherlands
    • 9.3.1. Nanomedicine Industry in Europe
    • 9.3.2. CriPec Based Nanomedicines - Overcome the Drawbacks of Conventional Therapies
    • 9.3.3. CriPec Platform - All the Best Features in a Single System
    • 9.3.4. CriPec Docetaxel - Lead Candidate Product
    • 9.3.5. In Development - CriPec Actively Targeted Nanoparticles Platform
    • 9.3.6. Competitive Advantage Can be Achieved Through Partnering of Parties

10. Conclusions of the Research and Analysis

  • 10.1. Nanotechnology Holds Great Promise in Healthcare
  • 10.2. More Research Needed to Establish Safety
  • 10.3. Harmonization in Definition and Guidelines

List of Tables

  • Table 1.1: The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 2.1: Advantages of Nanotechnology in Medicine
  • Table 2.2: Challenges and Solutions - NDDS
  • Table 3.1: The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.2: Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.3: Global Nanomedicine CVD Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.4: Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.5: Global Nanomedicine CNS Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.6: Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.7: Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.1: Abraxane Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.2: Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.3: Eligard Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.4: Copaxone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.5: Rapamune Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.6: Neulasta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.7: Cimzia Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.8: AmBisome Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.9: MIRCERA Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.10: Pegasys Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.11: Emend Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.12: Renagel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.13: Ritalin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.1: Nanomedicine Market Revenues ($bn) for Leading Regions, 2014-2025
  • Table 5.2: Nanomedicine Market Share(%) by Leading Regions, 2014-2025
  • Table 5.3: Prominent Nanomedicine Companies in the US, 2014
  • Table 5.4: The US Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.5: The Japanese Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.6: EU Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.7: Prominent Nanomedicine Companies in the UK, 2014
  • Table 5.8: Prominent Nanomedicine Companies in Germany, 2014
  • Table 5.9: Prominent Nanomedicine Companies in France, 2014
  • Table 5.10: Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 5.11: RoW Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 8.1: Strengths, Weaknesses, Opportunities and Threats in the Nanomedicine Market, 2015

List of Figures

  • Figure 1.1: Nanomedicine - Segmented by Application
  • Figure 2.1: Applications of Nanotechnology in Diagnostics
  • Figure 2.2: Applications of Nanotechnology in Therapeutics
  • Figure 2.3: Systems Used in Nanotechnology-enabled Drug Delivery
  • Figure 2.4: Market Shares of NDDS by System, 2014
  • Figure 2.5: NDDS: Market Drivers and Restraints, 2015-2025
  • Figure 2.6: Representation of Nanoparticles
  • Figure 2.7: Combinations of Layers that Form Nanoparticles
  • Figure 2.8: Nanoparticles: Market Drivers and Restraints 2015-2025
  • Figure 2.9: Implants: Market Drivers and Restraints, 2015-2025
  • Figure 2.10: Diagnostics: Market Drivers and Restraints, 2015-2025
  • Figure 2.11: Theranostics: Market Drivers and Restraints, 2015-2025
  • Figure 3.1: Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.2: Applications of Nanotechnology in the Cardiovascular Therapeutic Area
  • Figure 3.3: Global Nanomedicine CVD Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.4: Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.5: Global Nanomedicine CNS Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.6: Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.7: Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), 2015-2025
  • Figure 4.1: Nanomedicine - Segmented by Application
  • Figure 4.2: Proportions of Nano Products by Application, 2014
  • Figure 4.3: Proportions of Nano Products by Therapeutic Area, 2014
  • Figure 4.4: Abraxane Revenue Forecast ($bn), 2015-2025
  • Figure 4.5: Alimta Revenue Forecast ($bn), 2015-2025
  • Figure 4.6: Eligard Revenue Forecast ($bn), 2015-2025
  • Figure 4.7: Copaxone Revenue Forecast ($bn), 2015-2025
  • Figure 4.8: Rapamune Revenue Forecast ($bn), 2015-2025
  • Figure 4.9: Neulasta Revenue Forecast ($bn), 2015-2025
  • Figure 4.10: Cimzia Revenue Forecast ($bn), 2015-2025
  • Figure 4.11: AmBisome Revenue Forecast ($bn), 2015-2025
  • Figure 4.12: MIRCERA Revenue Forecast ($bn), 2015-2025
  • Figure 4.13: Pegasys Revenue Forecast ($bn), 2015-2025
  • Figure 4.14: Emend Revenue Forecast ($bn), 2015-2025
  • Figure 4.15: Renagel Revenue Forecast ($bn), 2015-2025
  • Figure 4.16: Ritalin Revenue Forecast ($bn), 2015-2025
  • Figure 5.1: Leading National Nanomedicine Markets by Share of Global Market (%), 2014
  • Figure 5.2: Leading National Nanomedicine Markets by Share of Global Market (%), 2019
  • Figure 5.3: Leading National Nanomedicine Markets by Share of Global Market (%), 2025
  • Figure 5.4: The US Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
  • Figure 5.5: The Japanese Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
  • Figure 5.6: EU Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
  • Figure 5.7: Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
  • Figure 5.8: RoW Nanomedicine Market: Revenue Forecast ($bn), 2015-2025
  • Figure 7.1: Proportion of Products by Therapeutic Area in Clinical Trials, 2014
  • Figure 7.2: Products in Clinical Trials by Developmental Phase, 2014

Companies Listed

  • 3M
  • Abbott
  • Abraxis
  • Access
  • Accord Healthcare
  • Ademtech
  • Agave Biosystems
  • Alcon
  • Allergan
  • Alrise Biosystems
  • AMAG Pharmaceuticals
  • Amgen
  • ANABior
  • Antnano
  • Apotex
  • AquaNova
  • Arrowhead Research
  • Astellas
  • AstraZeneca
  • Avidimer
  • Axialys Innovations
  • Azaya Therapeutics
  • Baxalta
  • Bayer
  • BBInternational
  • BIND Biosciences
  • BIND Therapeutics
  • Bioalliance
  • BioCellChallenge
  • Biomerieux
  • BIOMET
  • BioNanomatrix
  • Calando Pharmaceuticals
  • Capsulution
  • CarlinaTechnologies
  • Celator
  • Celator Pharma
  • Celgene
  • Cell Constraint Cancer
  • Celsion Corporation
  • Cerulean Pharma
  • Cezanne
  • ChemBiotech
  • Chemicell
  • ChipShop
  • Cisbio
  • Colcom Nanotech
  • Committee for Medicinal Products for Human Use (CHMP)
  • Cytimmune
  • Cytoo
  • Cytoplex Biosciences
  • DCN Corp
  • Eli Lilly
  • EMA
  • Empa
  • EndoMagnetics
  • Enzon Pharmaceuticals
  • Epeius
  • Etex
  • Ethypharm
  • EU-Nano Characterization Lab (EUNCL)
  • FDA
  • Flamel Technologies
  • Fleet Bioprocessing
  • Fluigent
  • Fresenius
  • Galen
  • Genetic Immunity
  • Genzyme
  • Gilead
  • GSK
  • Guerbet
  • iCEUTICA
  • Immunigon
  • IMSTAR
  • Inanovate
  • Innova Biosciences
  • InoDiag
  • Intas
  • Invitrogen
  • Janssen
  • Keystone Nano
  • Kylin Therapeutics
  • Lighthouse Biosciences
  • Liquidia
  • LTT Bio-Pharma
  • Magforce
  • MagnaMedics
  • Mantis Deposition
  • MAST Carbon International
  • medsqual
  • Merck & Co.
  • Midatech
  • Momento
  • Mylan
  • NanoBio
  • Nanobiotix
  • Nanocarrier
  • Nanoco Technologies
  • NanoCor Therapeutics
  • NanoDel
  • Nanoforce
  • NanoMedSyn
  • Nanomerics
  • Nanopore
  • Nanoprobes
  • Nanosight
  • Nanospectra Biosciences
  • NatCo
  • National Characterization Laboratory (NCL)
  • National Nanotechnology Initiatives (NNI)
  • NIH
  • Nippon Kayaku Co.
  • Novagali Pharma
  • Novartis
  • Novavax
  • Novosom AG
  • NSD
  • Otsuka
  • Oxonica
  • OZ Biosciences
  • PDS Biotechnology
  • PF Prism
  • Pfizer
  • PharmaSol
  • Phusis
  • Polaris
  • PolyMicrospheres
  • ProNAi
  • PST
  • Pylote
  • Qiagen
  • QuantuMD
  • RegenTec
  • Responsif
  • Rexahn Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Selecta Biosciences
  • Siemens
  • Sigma-Tau
  • Silence Therapeutics
  • Silicon Kinetics
  • SkyePharma
  • Smith&Nephew
  • Smiths Medical
  • Spirogen
  • SRU Biosystems
  • SynerGene Therapeutics
  • Synthon
  • T2 Biosystems
  • Taiho
  • Teva Pharmaceuticals
  • UCB
  • XstalBio
  • Zell Kontakt
Back to Top